Şeyma Özden

Dr. Şeyma Özden


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 May 2023 in Journal of Asthma
Verified
Journal Article
Closed access
GCGulfem Elif Celik
Gulfem Elif Celik
OAOmur Aydin
Omur Aydin
DGDerya Gökmen
Derya Gökmen
GBGozde Koycu Buhari
Gozde Koycu Buhari
ZSZeynep Celebi Sözener
Zeynep Celebi Sözener
AYArzu Yorgancioglu
Arzu Yorgancioglu
National data on asthma characteristics and the factors associated with uncontrolled asthma seem to be necessary for every country. For this purpose, we developed the Turkish Adult Asthma Registry ...

23 September 2023 in World Allergy Organization Journal
Verified
Journal Article
Open access
FTFatma Merve Tepetam
Fatma Merve Tepetam
ŞÖŞeyma Özden
Şeyma Özden
FKFatma Kübra Kılıç
Fatma Kübra Kılıç
COCihan Orcen Orcen
Cihan Orcen Orcen
TYTugce Yakut
Tugce Yakut
Non-steroidal anti-inflammatory drug (NSAID)-exacerbated respiratory disease (N-ERD) accompanies severe asthma in about 15% of the patients and may adversely affect the prognosis. Omalizumab and mepolizumab are biologics used in patients with severe asthma. The objective of this study is to assess the respiratory improvements, after these biologics in severe asthmatic patients stratifed by the presence of concomitant Non-erosive reflux disease (N-ERD) and the effect of omalizumab and mepolizumab in severe asthmatics with N-ERD. The population of this three-center, retrospective, cross-sectional, observational study comprised patients using omalizumab or mepolizumab for severe asthma. Patients administered these biologics for severe asthma were comparatively analyzed for the presence of N-ERD; asthma control test (ACT) scores, number of attacks, and the changes in forced expiratory volume in 1 s (FEV1) were assessed. Subsequently, patients who were found to have N-ERD were analyzed using visual analog scale (VAS) in terms of the changes in their nasal parameters (ie, nasal obstruction, facial pain, anterior-posterior rhinitis, and hyposmia), according to whether they use omalizumab or mepolizumab. The use of biologics resulted in a significant improvement in ACT and FEV1 and reduction in attacks in 28 severe asthmatics with N-ERD and 125 without N-ERD. Although both biologics resulted in a significant improvement in the respiratory parameters, omalizumab treatment resulted in a significant improvement in nasal parameters except hyposmia, mepolizumab treatment resulted in a significant improvement only in posterior rhinitis, and nasal obstruction among the nasal parameters. This study is the first to address both omalizumab and mepolizumab treatments in severe asthmatics with N-ERD. The improvement in nasal parameters was more pronounced in patients who were administered omalizumab. Large-scale randomized controlled studies are needed to corroborate the findings of this study.

16 February 2025 in Journal of Asthma
Verified
Journal Article
Closed access
ZSZeynep Celebi Sözener
Zeynep Celebi Sözener
IOI.Kivilcim Oguzulgen
I.Kivilcim Oguzulgen
FAFunda Seher Ozalp Ates
Funda Seher Ozalp Ates
ABAyse Baccioglu
Ayse Baccioglu
SBSerap Argun Baris
Serap Argun Baris
GCGulfem Elif Celik
Gulfem Elif Celik
The obese-asthma phenotype has gradually increased in the last few years. We aimed to assess the differences between obese and non-obese patients with asthma. This research is a subanalysis of the Turkish Adult Asthma Registry (TAAR). Clinical presentation, disease control, severity, and demographics of obese and non-obese (lean, normal-weight, overweight) patients were compared. The obesity rate in TAAR was 32.2% (n = 619/1919; 18-83 years; 527 F/92 M). Patients with asthma and obesity had higher rates of childhood obesity, longer symptom duration, later onset of asthma, and more severe asthma. These patients were more likely to be female, older, less educated, and live in rural areas. Patients with obesity had more scheduled visits and emergency visits compared with non-obese patients, but similar asthma control, oral corticosteroid use, hospitalizations, intensive care unit admissions, and unscheduled visits. They also had a higher frequency of T2-high but lower frequency of possible T2-low phenotypes compared with normal-weight asthmatics. The risk of severe asthma in patients with obesity was 6.04 times higher for allergic than non-allergic patients and 3.58 times higher for the T2-high phenotype than for possible T2-low phenotypes. A one-unit increase in the asthma control test reduced the risk of severe asthma by 22%. A good definition of this phenotype is important to ensure that appropriate treatment strategies are implemented to achieve the control goal. We also believe that prevention of childhood obesity is an effective and pivotal strategy to achieve the goal of asthma control.

1 January 2024 in Northern Clinics of Istanbul
Verified
Journal Article
Open access
ŞÖŞeyma Özden
Şeyma Özden
IGIsil Gokdemir
Isil Gokdemir
MKMurat Kiyik
Murat Kiyik
OBJECTIVE: The aim of this study was to evaluate the relationship between the degree of visceral pleural invasion (VPI) and survival in patients operated for non-small cell lung cancer (NSCLC). METHODS: Between 2013 and 2015, 202 patients who were diagnosed with NSCLC in our center and followed up in our clinic were retrospectively evaluated. To examine the preoperative and postoperative prognostic factors of the patients, postoperative pathology results, demographic data and data on recurrence status were obtained from our hospital database and patient files. RESULTS: VPI Survival analysis was performed by dividing 3 groups: PL0, PL1 and PL2. Mean survival (MS) was calculated as 39.528 +/- 1.469 (36.655-42.402; 95% CI) months for PL0, 35.136 +/- 3.115 (29.031-41.240; 95% CI) months for PL1, and 24.688 +/- 3.697 (17.441-31.934; 95% CI) for PL2 (p=0.020). When we consider PL0 and PL1 as a single group and compare it with PL2, the MS time of the PL0-PL1 group was 38.358 +/- 1.346 (35.721-40.995; 95% CI) months, while the MS time of the PL2 group was 24.688 +/- 3.697 (17.441-31.934; 95% CI) months (p=0.020). CONCLUSION: Although PL0, PL1 and PL2 were classified into a single group (all considered as T2), this study showed that the presence of PL2 was associated with a poor prognosis in terms of survival, independent of lymph node involvement, histopathological subtype of the tumor and tumor size.

5 May 2023 in Medicine
Verified
Journal Article
Open access
FTFatma Merve Tepetam
Fatma Merve Tepetam
AAAli Burkan Akyildiz
Ali Burkan Akyildiz
ŞÖŞeyma Özden
Şeyma Özden
COCihan Orcen Orcen
Cihan Orcen Orcen
TYTugce Yakut
Tugce Yakut
ÖAÖzge Atik
Özge Atik
Approximately 1-third of patients with severe asthma are candidates for both omalizumab and mepolizumab treatment. We aimed to compare the clinical, spirometric and inflammatory efficacy of these 2 biologics in atopic and eosinophilic “overlap” severe asthma patients. In our 3-center retrospective cross-sectional observational study, the data of patients who received omalizumab or mepolizumab for at least 16 weeks to treat severe asthma were examined. Atopic (perennial allergen sensitivity and total IgE level 30–1500 IU/mL) and eosinophilic (blood eosinophil counts ≥150 cells/µL in admission; or ≥300 cells/µL in the previous year) patients with asthma suitable for both biologics were included in the study. Post-treatment changes in the asthma control test (ACT) score, number of attacks, forced expiratory volume in 1 second (FEV1), and eosinophil count were compared. The rates of any biological responder patient were compared according to whether they had high eosinophil counts (≥500 cells/µL vs <500 cells/µL). Total of 181 patients data were evaluated, of the 74 atopic and eosinophilic overlap patients included in the study, 56 were receiving omalizumab and 18 were receiving mepolizumab. When omalizumab and mepolizumab treatment efficacies were compared, there was no difference in terms of the reduction in attacks and improvement in ACT. The decrease in eosinophil levels in patients in the mepolizumab arm was significantly higher than that in patients in the omalizumab arm (46.3% vs 87.8%; P < .001). The improvement in FEV1 was greater with mepolizumab treatment, although the difference was not significant (215 mL vs 380 mL; P = .053). It has been shown that having high eosinophil counts does not affect the clinical and spirometric responder patient rates for either biological condition. The success of omalizumab and mepolizumab treatment is similar in patients with atopic and eosinophilic overlap with severe asthma. However, because the baseline patient inclusion criteria are not compatible, head-to-head studies comparing both biological agents are required.

25 January 2024 in International Archives of Allergy and Immunology
Verified
Journal Article
Closed access
PDF file
ŞÖŞeyma Özden
Şeyma Özden
FTFatma Merve Tepetam
Fatma Merve Tepetam
ÖAÖzge Atik
Özge Atik
Introduction: Iron deficiency is the most common cause of anemia in both sexes, although it is more common in women. Intravenous (IV) iron replacement is preferred in patients who cannot tolerate oral treatment or when iron stores need to be replenished rapidly. In this study, we wanted to share the ferric carboxymaltose (FCM) desensitization protocol that we self-created and successfully applied. Methods: This retrospective cross-sectional study included patients with a history of hypersensitivity reactions (HSRs) to IV or oral iron replacement and patients who were planned to receive IV iron replacement but were referred to the allergy clinic because of have risk factors (atopic diseases, history of HSR to other drugs, high serum tryptase levels, etc.) for HSRs. Before desensitization, some of the patients underwent skin tests (skin prick test and intradermal test) with FCM, and the results were recorded. Skin tests were not performed in patients with a history of drug use (antihistamine, systemic steroid, omalizumab, etc.) that affected the results of skin tests. All patients underwent a one-bag 8-step desensitization protocol with 500 mg FCM and were observed for 2 h after desensitization. Results: A total of 15 patients (14 females and 1 male) with a mean age of 41.13 ± 11.18 years were included in the study. When the patients were evaluated in terms of the risk of allergic reactions according to their clinical history, 8 patients had a history of anaphylaxis with iron preparations (FCM, n = 4; ferric hydroxide sucrose, n = 2; iron [II] glycine sulfate, n = 1; and iron [III] hydroxide polymaltose, n = 1), and 7 patients had a history of HSR other than anaphylaxis with iron preparations (urticaria, n = 6 [FCM, n = 2; iron (II) glycine sulfate, n = 2; and iron (III) hydroxide polymaltose, n = 2] and urticaria + angioedema [ferric hydroxide sucrose, n = 1]). Desensitization was successfully completed in all patients. No HSR was observed during or after the procedure in any of the patients. Conclusion: IV iron replacement is a very effective method, especially in cases where iron stores need to be replenished more rapidly. In patients with a history of iron HSR or at risk of developing HSR, replacement can be safely performed without an allergic reaction with successful desensitization protocols.